To explore the therapeutic potential of targeting Itpkb for T cell-mediated autoimmune diseases, a selective, potent, and orally bioavailable LMW inhibitor of Itpkb, GNF362, was identified via high-throughput compound screening and optimized for drug-like properties using medicinal chemistry. This evidence concerns the gene ITPKB and autoimmune disease.